Document is current
Any future updates will be listed below
-
Authors
Park, Hyun Young https://orcid.org/0000-0002-1673-6392
Joo, Kwangsic https://orcid.org/0000-0003-4266-1491
Woo, Se Joon https://orcid.org/0000-0003-3692-7169
-
Funding
Funding for this research was provided by:
Ministry of Health & Welfare, Republic of Korea (RS-2025-02263279)
- License Information
-
More Information
Article History
Received: 22 December 2025
Accepted: 30 March 2026
First Online: 8 April 2026
Declarations
:
: This study was approved by the Institutional Review Board (IRB) of Seoul National University Bundang Hospital (IRB No. B-2508-993-106) and was conducted in accordance with the tenets of the Declaration of Helsinki. The requirement for informed consent was waived due to the retrospective nature of the study.
: Not applicable.
: Se Joon Woo received consulting fees from Alteogen, Astellas, Boeringer Ingelheim, Curacle, Janssen, Novelty Nobility, Pharmabcine, Optus, Samsung Bioepis, Samil, Sometech, lecture fees from Alcon, Bayer, Novartis, Abbvie, Roche, Santen, Samil, Zeiss; grants from Samsung Bioepis, Alcon, Alteogen, Curacle, Kyowa Kirin, Novelty Nobility, Novartis, Pharmabcine, Roche, Zeiss; owns equity of RetiMark and Panolos Bioscience.
